Pancytopenia as an early indicator for Stevens-Johnson syndrome complicated with hemophagocytic lymphohistiocytosis: a case report by Zhi-Dan Fan et al.
Fan et al. BMC Pediatrics 2014, 14:38
http://www.biomedcentral.com/1471-2431/14/38CASE REPORT Open AccessPancytopenia as an early indicator for
Stevens-Johnson syndrome complicated with
hemophagocytic lymphohistiocytosis: a case
report
Zhi-Dan Fan, Xiao-Qing Qian and Hai-Guo Yu*Abstract
Background: Stevens-Johnson syndrome (SJS) is a severe skin and mucosal bullous disease. When complicated
with Hemophagocytic lymphohistiocytosis (HLH), the condition is especially life-threatening.
Case presentation: Here we report the case of a 4-year-old boy suffering from SJS with extensive erythema multiforme
and bulla. Despite active intervention and supportive care, the boy experienced increased skin lesions and a higher
fever. Meanwhile, decreases in white blood cell count and hemoglobin were observed. Hyperferritinemia, increased
soluble CD25 level, decreased NK cell activity and hemophagocytosis in the boy’s bone marrow confirmed the diagnosis
of HLH. After high-dose intravenous immunoglobulin and methylprednisone pulse therapy, the boy was discharged in
good condition.
Conclusion: Simultaneous occurrence of HLH and SJS is very uncommon and the condition is life-threatening.
Pancytopenia can be a precocious indicator and enables to start a prompt diagnosis and treatment.
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Stevens-Johnson syndrome (SJS) is characterized mor-
phologically by the rapid onset of epidermal detachment
and erosion of the mucous membrane. Epithelial loss
and the subsequent bacterial and fungal infections are
the most common cause of death in patients with SJS
[1]. Immune dysregulation plays a key role in the patho-
genesis of SJS. The death-inducing interaction of Fas
with its Fas ligand triggers a suicidal caspase cascade in
epidermal cells. High-dose intravenous immunoglobulin
(IVIG) was shown to contain natural Fas-blocking anti-
bodies and thus abrogate the keratinocyte apoptosis and
the subsequent epidermal detachment [2].
Hemophagocytic lymphohistiocytosis (HLH), a lethal
immune disorder, often leads to an abrupt onset of
single organ failure and rapid progression to multiple* Correspondence: yuhaiguo73@126.com
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stated.organ failure [3]. Unlike familial HLH due to genetic de-
fects leading to impaired functions of natural killer and
cytotoxic T cells, secondary HLH is generally triggered
by infections, immunosuppressant drugs, malignant or
rheumatologic disorders [4]. So far, in patients with SJS,
HLH has been rarely reported [5]. However, SJS compli-
cated with HLH is a life-threatening condition as the
diagnosis often occurs too late to start timely life-saving
therapy. Here we report a 4-year-old boy who developed
HLH following SJS. The laboratory tests of pancytopenia
can be a precocious indicator for us to make a prompt
diagnosis, and to start a timely treatment to ensure the
successful outcome.Case presentation
A previously healthy 4-year-old boy was admitted to our
pediatric intensive care unit with a one-week history of
spiking fever, coughing and a three-day history of severe
mucous membrane and skin lesions. He received some
cephalosporin and ibuprofen in another hospital for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical and laboratory parameters at diagnosis







1. Fever Yes No
2. Splenomegaly No No
3. Cytopenias (≥2 lineages)
Hemoglobin (g/L) 79 125 <90
Platelets (×109/L) 198 332 <100
Neutrophils (×109/L) 0.01 2.38 <1.0
4. Hypertriglyceridemia and/
or hypofibrinogenemia
Triglycerides (mmol/L) 1.98 0.69 ≥3.0
Fibrinogen (g/L) 4.2 5.3 ≤1.5
5. Hemophagocytosis Yes (bone
marrow)
6. NK cell activity (%) 1.02 19.39 ≤8
7. Ferritin (μg/L) 1031 259 ≥500
8. Soluble CD25 (U/ml) 8910 1341 ≥2400
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four days of treatment, he developed a higher fever and
a raised erythematous rash.
On admission, the boy appeared unwell with tem-
perature above 39°C and heart rate of 192 beats/min.
The examination showed oral mucositis, vesicobullous
lesions and skin detachment across the body (Figure 1).
Routine blood tests were unremarkable on admission.
Biochemistry parameters were normal except for albumin
(27 g/L [normal 35–55]) and serum sodium (126 mmol/L
[normal 135–145]). Both erythrocyte sedimentation rate
(61 mm/h [normal < 20]) and C-reactive protein (85 mg/L
[normal < 10]) were markedly increased. The pathological
and bacteriologic examinations indicated the absence of
viral, mycoplasma pneumoniae and chlamydia pneumo-
niae infections and negative results of blood culture and
galactomannan test.
The active intervention, anti-infection measures, fluid
compensation, electrolyte balance, nutritional support
and intensive care were initiated immediately after
hospitalization with SJS. Meanwhile, high-dose IVIG
(2 g/kg, single continuous infusion) was given since
IVIG can inhibit Fas-FasL interaction and halt the pro-
gression of SJS. HLH was suspected when the patient’s
condition continued to deteriorate with hyperpyrexia
and pancytopenia. Routine blood monitoring revealed
anemia (hemoglobin 79 g/L), leukopenia (white blood
cell count 0.6 × 109/L) and agranulocytosis (neutrophils
0.01 × 109/L). Then the HLH was suspected and the
ferritin, NK cells and soluble CD25 were measured. Also
the bone marrow smear was performed.
The diagnosis of SJS-associated HLH was established
since the patient fulfilled 6 out of 8 HLH-2004 diagnos-
tic criteria (Table 1) [4]. The laboratory tests showedFigure 1 Serious oral mucosal erosions, vesicobullous lesions
and skin detachment across the body.hyperferritinemia (1031 μg/L), increased soluble CD25
level (8910 U/ml), decreased NK cell activity (1.02%)
and hemophagocytosis in bone marrow (Figure 2).
Then pulse methylprednisolone (15 mg/kg/day) was
administered for 3 consecutive days. The syndrome was
considered to be in remission when the patient’s general
condition improved, with normal temperature, amelio-
rated rash and normal routine blood examinations. Here-
after, methylprednisolone was continued at 2.5 mg/kg/day
for another 3 days followed with appropriate rapid tape-
ring by 20 mg every 3 days. His condition progressively
improved, with normal hematological and biochemical
laboratory parameters, inflammatory indices and ferritin
level. On the day before discharge in good condition,Figure 2 Hemophagocytosis in the bone marrow in our patient.
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absence of hemophagocytosis. Some known genetic
defects including PRF1, UNC13D and STX11 were ex-
amined to exclude the familial HLH but no mutations
were found.
Discussion
Secondary HLH has been described mainly in association
with viral, bacterial, fungal, and parasitic infections, malig-
nant or rheumatologic disorders [4]. There is substantial
mortality in secondary HLH, depending on the underlying
disease [3]. So far, HLH has seldom been reported in pa-
tients with SJS. It should be noted that both SJS and HLH
have a high mortality rate, so concurrence of the two in a
patient is especially danger. Matsumoto Y. et al. [5] re-
ported a 34-year-old woman who presented SJS compli-
cated with HLH. Although repeated plasmapheresis was
conducted, the woman still died of a brain hemorrhage
due to disseminated intravascular coagulation.
Until recently, the pathophysiological mechanisms of
secondary HLH are incompletely elucidated. The degree
of cytokine disturbance is closely related to clinical signs
and symptoms [6]. HLH often carries a very bad progno-
sis for being underdiagnosed and undertreated [7]. At
the early stage before proinflammatory damage and
cytokine storm, the opportunity to prompt recovery in
effective treatment was often missed [8]. Furthermore, it
is important for clinicians to differentiate HLH from
underlying disease flares or infectious complications
because they may share nearly all clinical and laboratory
characteristics.
The timely awareness and diagnosis of HLH is the
first, crucial step toward successfully life-saving therapy
but is challenging because HLH is always complicated
by relatively non-specific and variable presentations.
NK-cell activity is typically low or absent in HLH, and
should be also measured post remission [9]. CD25 is a
useful inflammatory marker correlating with disease
activity. But obtaining these two results required time.
Hyperferritinemia is proved to be a valuable disease
marker of HLH. An elegant study by Allen CE et al. [10]
showed that a ferritin level over 10,000 ng/ml in
children was 90% sensitive and 96% specific for HLH.
Hemophagocytosis is important in the diagnostic work-
up of HLH [4]. However, the sensitivity of hemophago-
cytosis was 83% with a specificity of only 60% for HLH
[11]. Moreover, hemophagocytosis may be lacking early
at onset. Waiting for evidence of hemophagocytosis to
make therapeutic decisions in the bone marrow may
delay appropriate therapy in this life-threatening condi-
tion [12]. It is important to note that these diagnostic
criteria are mainly helpful in making the diagnosis in-
stead of reflecting all of the typical clinical or laboratory
features of patients with HLH. Of the ubiquitousresponses in HLH, the pancytopenia is the most com-
mon feature and this can be easily detected by routine
blood monitoring. HLH diagnosis is based on progres-
sive cytopenia affecting at least two cell lineages. Consid-
ering the incidence of pancytopenia is very low in SJS, it
can be an early indicator for SJS complicated with HLH
and enables clinicians to start a prompt diagnosis and a
timely life-saving therapy.
Therapeutic strategies for secondary HLH are not well
established because randomized controlled clinical trails
are not available [13]. However, based on our own
experience [14] and some multi-center cohort studies
[15], the initial treatment should be capable of suppressing
the severe hyper-inflammation and controlling the under-
lying disease. A recent analysis of our experience treating
23 secondary HLH patients (so-called macrophage activa-
tion syndrome) triggered by systemic onset juvenile idio-
pathic arthritis, Kawasaki disease and systemic lupus
erythematosus showed that 21 children were successfully
treated with IVIG, corticosteroid and cyclosporine A. Cor-
ticosteroid and/or immunosuppressants seem to be the
mainstay of treatment for secondary HLH [16]. When the
trigger event is SJS per se in our patient, IVIG and cortico-
steroid are proposed to be first line therapeutic tools
according to the HLH-2004 protocol [4]. High-dose IVIG
can be given before a definite diagnosis of HLH since
IVIG can halt the progression of SJS. In addition, we
deemed that early use of IVIG may prevent a cytokine
storm in HLH through the blockade of Fc receptors and
other pathways. After establishing diagnosis of secondary
HLH, the corticosteroid should be used to counteract the
activated macrophages and stop the hyperinflammation
stage of the syndrome.
Conclusions
In conclusion, HLH in SJS is very uncommon and the
condition is life-threatening. IVIG in combination with
corticosteroid is a safe and effective therapeutic regimen.
Keeping highly vigilant to make an early diagnosis is es-
sential to ensure favorable outcomes. Pancytopenia can
be a precocious indicator and enables to start a prompt
diagnosis and treatment.
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